Malaria vaccine research & innovation: the intersection of IA2030 and zero malaria.
作者信息
Kaslow David C
机构信息
PATH, 2201 Westlake Avenue, Suite 200, Seattle, WA, 98121, USA.
出版信息
NPJ Vaccines. 2020 Nov 20;5(1):109. doi: 10.1038/s41541-020-00259-3.
Abstract
摘要
相似文献
1
Malaria vaccine research & innovation: the intersection of IA2030 and zero malaria.疟疾疫苗研究与创新：IA2030与零疟疾的交汇点
NPJ Vaccines. 2020 Nov 20;5(1):109. doi: 10.1038/s41541-020-00259-3.
2
Accelerating access for all through research and innovation in immunization: Recommendations from Strategic Priority 7 of the Immunization Agenda 2030.通过免疫研究和创新加速全民获得免疫服务：《2030 年免疫议程》战略重点 7 的建议。
Vaccine. 2024 Apr 8;42 Suppl 1:S82-S90. doi: 10.1016/j.vaccine.2022.11.041. Epub 2022 Dec 16.
3
Achieving the IA2030 Coverage and Equity Goals through a Renewed Focus on Urban Immunization.通过重新聚焦城市免疫接种实现2030年免疫接种覆盖和公平目标。
Vaccines (Basel). 2023 Apr 6;11(4):809. doi: 10.3390/vaccines11040809.
4
Global vaccine action plan lessons learned I: Recommendations for the next decade.全球疫苗行动计划经验教训 I：下一个十年的建议。
Vaccine. 2020 Jul 14;38(33):5364-5371. doi: 10.1016/j.vaccine.2020.05.003. Epub 2020 May 5.
5
Producing a successful malaria vaccine: innovation in the lab and beyond.生产一种成功的疟疾疫苗：实验室内外的创新。
Health Aff (Millwood). 2011 Jun;30(6):1065-72. doi: 10.1377/hlthaff.2011.0356.
6
Building momentum for malaria vaccine research and development: key considerations.为疟疾疫苗研究和开发提供动力：关键考虑因素。
Malar J. 2020 Nov 23;19(1):421. doi: 10.1186/s12936-020-03491-3.
7
A Systematic Framework for Prioritizing Burden of Disease Data Required for Vaccine Development and Implementation: The Case for Group A Streptococcal Diseases.用于确定疫苗开发和实施所需疾病负担数据优先级的系统框架：以A群链球菌疾病为例
Clin Infect Dis. 2022 Sep 30;75(7):1245-1254. doi: 10.1093/cid/ciac291.
8
Plasmodium vivax transmission-blocking vaccines: Progress, challenges and innovation.疟原虫 vivax 传播阻断疫苗：进展、挑战与创新。
Parasitol Int. 2022 Apr;87:102525. doi: 10.1016/j.parint.2021.102525. Epub 2021 Dec 9.
9
Paths to a malaria vaccine illuminated by parasite genomics.寄生虫基因组学揭示的疟疾疫苗之路
Trends Genet. 2015 Feb;31(2):97-107. doi: 10.1016/j.tig.2014.12.005. Epub 2015 Jan 22.
10
Effect of intermittent preventive treatment for malaria with dihydroartemisinin-piperaquine on immune responses to vaccines among rural Ugandan adolescents: randomised controlled trial protocol B for the 'ulation differences in cine responses' (POPVAC) programme.二氢青蒿素-哌喹间歇性预防治疗疟疾对乌干达农村青少年疫苗免疫反应的影响：“人群疫苗反应差异”（POPVAC）计划的随机对照试验方案 B。
BMJ Open. 2021 Feb 16;11(2):e040427. doi: 10.1136/bmjopen-2020-040427.
引用本文的文献
1
Innovative Multistage ML-QSAR Models for Malaria: From Data to Discovery.用于疟疾研究的创新多阶段机器学习定量构效关系模型：从数据到发现
ACS Med Chem Lett. 2024 Jul 18;15(8):1386-1395. doi: 10.1021/acsmedchemlett.4c00323. eCollection 2024 Aug 8.
2
Subcutaneous Immunization with Unaltered Axenic Malaria Parasite Liver Stages Induces Sterile Protection against Infectious Sporozoite Challenge.用未改变的无菌疟疾寄生虫肝期进行皮下免疫可诱导对感染性子孢子攻击的无菌保护。
Vaccines (Basel). 2022 Nov 8;10(11):1884. doi: 10.3390/vaccines10111884.
3
Genetic diversity and immunogenicity of the merozoite surface protein 1 C-terminal 19-kDa fragment of Plasmodium ovale imported from Africa into China.非洲输入中国卵形疟原虫裂殖子表面蛋白 1 羧基端 19kDa 片段的遗传多样性和免疫原性。
Parasit Vectors. 2021 Nov 24;14(1):583. doi: 10.1186/s13071-021-05086-6.
4
Towards Eradication of Malaria: Is the WHO's RTS,S/AS01 Vaccination Effective Enough?迈向消除疟疾：世界卫生组织的RTS,S/AS01疫苗是否足够有效？
Risk Manag Healthc Policy. 2021 Mar 12;14:1033-1039. doi: 10.2147/RMHP.S219294. eCollection 2021.
本文引用的文献
1
Immunization agenda 2030: A global strategy to leave no one behind.《2030年免疫议程：不让任何人掉队的全球战略》
Vaccine. 2024 Apr 8;42 Suppl 1:S5-S14. doi: 10.1016/j.vaccine.2022.11.042.
2
Malaria vaccines since 2000: progress, priorities, products.2000年以来的疟疾疫苗：进展、优先事项与产品
NPJ Vaccines. 2020 Jun 9;5(1):48. doi: 10.1038/s41541-020-0196-3. eCollection 2020.
3
Evolution of protective human antibodies against Plasmodium falciparum circumsporozoite protein repeat motifs.抗疟原虫环子孢子蛋白重复基序的保护性人抗体的进化。
Nat Med. 2020 Jul;26(7):1135-1145. doi: 10.1038/s41591-020-0881-9. Epub 2020 May 25.
4
Antibody response of a particle-inducing, liposome vaccine adjuvant admixed with a Pfs230 fragment.与Pfs230片段混合的颗粒诱导脂质体疫苗佐剂的抗体反应。
NPJ Vaccines. 2020 Mar 18;5(1):23. doi: 10.1038/s41541-020-0173-x. eCollection 2020.
5
Amplification of Duffy binding protein-encoding gene allows Plasmodium vivax to evade host anti-DBP humoral immunity.Duffy 结合蛋白编码基因的扩增使间日疟原虫逃避宿主抗 DBP 体液免疫。
Nat Commun. 2020 Feb 19;11(1):953. doi: 10.1038/s41467-020-14574-9.
6
Immunization with full-length merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial.在一项随机的人体首次试验中，用全长裂殖子表面蛋白1进行免疫接种是安全的，并能引发功能性嗜细胞抗体。
NPJ Vaccines. 2020 Jan 31;5(1):10. doi: 10.1038/s41541-020-0160-2. eCollection 2020.
7
AgBR1 antibodies delay lethal -borne West Nile virus infection in mice.抗AgBR1抗体可延缓小鼠因接触致死剂量西尼罗河病毒而导致的感染。
NPJ Vaccines. 2019 Jul 8;4:23. doi: 10.1038/s41541-019-0120-x. eCollection 2019.
8
Structural basis for inhibition of Plasmodium vivax invasion by a broadly neutralizing vaccine-induced human antibody.结构基础为广泛中和疫苗诱导的人抗体抑制间日疟原虫入侵。
Nat Microbiol. 2019 Sep;4(9):1497-1507. doi: 10.1038/s41564-019-0462-1. Epub 2019 May 27.
9
Structural basis for neutralization of Plasmodium vivax by naturally acquired human antibodies that target DBP.靶向 DBP 的天然人源抗体中和间日疟原虫的结构基础。
Nat Microbiol. 2019 Sep;4(9):1486-1496. doi: 10.1038/s41564-019-0461-2. Epub 2019 May 27.
10
Pregnant women & vaccines against emerging epidemic threats: Ethics guidance for preparedness, research, and response.孕妇与新兴传染病威胁疫苗：备灾、研究和应对的伦理指导
Vaccine. 2021 Jan 3;39(1):85-120. doi: 10.1016/j.vaccine.2019.01.011. Epub 2019 May 3.
Zotero 插件